Crossmark

Introducing a revised version of the Kumamoto scale as an easy-to-use clinical tool for monitoring multisystemic changes in hereditary transthyretin amyloidosis

Crossref DOI link: https://doi.org/10.1186/s13023-025-03915-w

Published Online: 2025-07-25

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Wixner, Jonas https://orcid.org/0000-0002-1536-1277
Pilebro, Björn

Wien, Tale N.

Eldhagen, Per

Mölgaard, Henning

Hedström, Björn

Terkelsen, Astrid J.
Funding

Funding for this research was provided by:

Västerbotten Läns Landsting (RV-995135)

Novo Nordisk Pharma (NNF23OC0082689)

Umea University
License Information

Text and Data Mining valid from 2025-07-25

Version of Record valid from 2025-07-25
More Information

Article History

Received: 15 January 2025

Accepted: 9 July 2025

First Online: 25 July 2025

Declarations

:

: Alnylam Pharmaceuticals sponsored the Nordic Amyloidosis Day but did not participate in the planning of the study or in the writing of the manuscript. The authors have no other conflicts of interest to declare for this publication.

: Since no patient data was included, no consent for publication was needed.

: No new data was collected and, thus, no ethical approval or consent to participate was necessary for the study.

Document is current

Any future updates will be listed below